Clinical Trial Update: An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a fixed-dose combination of candesartan and amlodipine for essential hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Candesartan/amlodipine fixed-dose combination (candesartan and amlodipine)

Snippet

Sponsor: Takeda | Conditions: Hypertension | Phase 3 | Status: WITHDRAWN